Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna Rallies on US Government Grant for Coronavirus Vaccine

by Zacks Equity Research

Moderna (MRNA) gets a commitment of up to $483 million from the U.S. Government Agency BARDA to accelerate the development of its mRNA-based coronavirus vaccine.

Zacks Equity Research

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Nalak Das headshot

Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results

by Nalak Das

The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.

Ritujay Ghosh headshot

Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D

by Ritujay Ghosh

Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.

Zacks Equity Research

Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine

by Zacks Equity Research

Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.

Ritujay Ghosh headshot

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

by Ritujay Ghosh

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

Zacks Equity Research

BioCryst Begins Study on Galidesivir for Coronavirus Infection

by Zacks Equity Research

BioCryst (BCRX) starts recruitment for a clinical study on its pipeline candidate galidesivir to treat patients with the deadly coronavirus disease.

Zacks Equity Research

Pfizer (PFE) Progressing Well With its Coronavirus Program

by Zacks Equity Research

Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.

Neena Mishra headshot

Coronavirus Testing, Vaccines & Treatments: What You Should Know

by Neena Mishra

We discuss latest developments in tests, vaccines and therapies for COVID-19.

Zacks Equity Research

Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate

by Zacks Equity Research

Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.